ESMO 2023 | Novel advances in cholangiocarcinoma

Lorenza Rimassa, MD, Humanitas University, Milan, Italy, provides an overview of current and future targeted therapies for patients with cholangiocarcinoma (CCA). For patients who have progressed on systemic therapy, pemigatinib and futibatinib are options for patients with FGFR2-mutant CCA, whereas ivosidenib has been approved for IDH1-mutant CCA. Novel therapies under investigation targeting HER2 mutations include zanidatamab, pertuzumab with trastuzumab, and pembrolizumab. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.